Emyria Ltd EMD
ASX · Australia · Technology Services
AUD 0.04500.00 (0.00%)
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · AUD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The S&P/ASX Small Ordinaries (ASX:XSO) closed at 3,500.90, down 0.38% or 13.40 points yesterday. The small-cap benchmark has lost further ground over the past 5 trading days, declining 1.62% or 57.60 points over the period. Against the softer index backdrop, several companies have...
Insiders who bought Emyria Limited ( ASX:EMD ) stock lover the last 12 months are probably not as affected by last...
Australia's largest private health insurer expands its AUD $10M psychotherapy program to cover psilocybin for Treatment-Resistant Depression, building on earlier MDMA coverage for PTSDVancouver, British Columbia--(Newsfile Corp. - October 6, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian GMP-compliant manufacturer of MDMA and psilocybin, today announced that its 5mg naturally-derived psilocybin capsules have been selected for inclusion..
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.